Overview
VIP is classified as a neuropeptide peptide. Systemic anti-inflammation, CIRS/mold illness treatment, pulmonary vasodilation, immune modulation.
28-amino acid neuropeptide that binds VPAC1 and VPAC2 receptors, activating cAMP pathways to produce broad anti-inflammatory effects. Inhibits TNF-alpha, IL-6, and IL-12 production while promoting Th2/Treg tolerance. Potent pulmonary vasodilator and bronchodilator. Used in the Shoemaker CIRS protocol for Chronic Inflammatory Response Syndrome (biotoxin illness) to correct TGF-beta 1 dysregulation and restore immune homeostasis.
Also known as: Vasoactive Intestinal Peptide, Vasoactive Intestinal Polypeptide
Category
Neuropeptide
Half-Life
0.033h
Route
Nasal
FDA Status
Not Approved
How Does VIP Work?
28-amino acid neuropeptide that binds VPAC1 and VPAC2 receptors, activating cAMP pathways to produce broad anti-inflammatory effects. Inhibits TNF-alpha, IL-6, and IL-12 production while promoting Th2/Treg tolerance. Potent pulmonary vasodilator and bronchodilator. Used in the Shoemaker CIRS protocol for Chronic Inflammatory Response Syndrome (biotoxin illness) to correct TGF-beta 1 dysregulation and restore immune homeostasis.
At the molecular level, VIP operates through pathways characteristic of the Neuropeptide class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]VIP is an autocrine growth factor for normal lung epithelium and as a growth factor and vasoactive compound for inflammatory conditions
Shoemaker et al.: Documents the use of intranasal VIP in CIRS patients, demonstrating normalization of TGF-beta 1, MMP-9, and VEGF, and improvement in pulmonary arterial pressure and NeuroQuant brain imaging abnormalities.
Evidence: emerging[2]Vasoactive intestinal peptide inhibits TLR4-induced inflammatory signaling in macrophages
Delgado et al.: VIP potently inhibits TLR4-mediated NF-kB activation and subsequent cytokine production (TNF-alpha, IL-6, IL-12) in macrophages, establishing its role as an endogenous immunomodulator.
Evidence: preclinicalSafety Profile
Not FDA-approved for general use. Used in the Shoemaker CIRS protocol under practitioner supervision. Very short plasma half-life (~2 min). Should only be used after completing prior CIRS treatment steps. May cause facial flushing and hypotension at higher doses.
| Side Effect | Incidence | Severity |
|---|---|---|
| Facial flushing | ~25% | mild |
| Hypotension | ~10% | mild |
| Nasal irritation | ~8% | mild |
Sourcing VIP for Research
If you're looking to source VIP for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
VIP — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.